Equillium, Inc.

We're happy to announce topline data from our Phase 3 EQUATOR study in acute graft-versus-host disease (aGVHD).?Treatment with itolizumab did not improve complete response (CR) of overall response (OR) rates at Day 29, but did achieve statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including CR at Day 99, duration of CR and failure free survival. - Stat sig in duration of CR favoring itolizumab, with a median 336 days vs. 72 days, p-value 0.017 - Stat sig in failure-free survival favoring itolizumab, with a median 154 vs. 70 days, p-value 0.043 - Stat sig in complete response at Day 99 favoring itolizumab, with 35 (44.9%) vs. 22 (28.6%) patients, p-value 0.035 - Positive trend in overall survival favoring itolizumab, with mortality of 19 (24.4%) vs. 25 (32.5%) patients Based on these data, encouraging feedback from leading KOLs, and prior FDA guidance, we have filed for Breakthrough Therapy designation and have a meeting with the agency to discuss potential for Accelerated Approval of itolizumab, which has already received Orphan Drug and Fast Track designations in this indication. We expect feedback from the FDA within 60 days, and if positive we would plan to submit a biologics license application during the first half of 2026. Full press release here: https://lnkd.in/gnAGUuBG Webcast here: https://lnkd.in/gsAejSiJ

From our humble table to yours, happy Thanksgiving.

Today we announced that an abstract was accepted for poster presentation at the 39th?Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Title:?Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses Presenting Author:?Phoi Tiet, Senior Research Associate, Equillium, Inc. Abstract Number: 908 Location:?Exhibit Halls A & B Date:?Saturday, November 9, 2024 The abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonstrates that IL-15 and IL-21 synergistically augment NK and CD8 T cells activities, which further enhanced their proliferation and cytolytic function. With the ability to rescue T cell dysfunction, this cytokine combination could be a promising treatment approach to stimulating anti-tumor immune responses.

Reminder...Get out and walk to end Lupus! https://walktoendlupus.org

Help us #WalktoEndLupusNow. Gather your friends, raise some $ and earn the exclusive Walk t-shirt when you hit $100! Register today at https://walktoendlupus.org

Join us on September 28 as we #WalkForAlopecia to help raise money for @NAAF_org https://www.naaf.org/walk/

It's conference season again! Equillium, Inc. presenting tomorrow, Tuesday, September 10th at 8:00 am ET at the H.C. Wainwright & Co., LLC Investor Conference. CEO, Bruce Steel, will provide an update on the full pipeline and milestones, including itolizumab and our Ono Pharmaceutical partnership. Live webcast and replay available on EQs events page: https://lnkd.in/gsAejSiJ

Equillium CEO, Bruce Steel, presenting today at 4:30 pm ET at the 2024 Wells Fargo Healthcare Conference in Boston. Presentation will provide an overview of the EQ's multi-cytokine inhibitor programs and platform, currently focused on dermatological and gastrointestinal indications, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical and Ono’s pending option exercise decision to potentially acquire Equillium’s rights to itolizumab. https://lnkd.in/gsAejSiJ

Please join us in welcoming our newest Clinical Operations Team member, Annie Huynh.?She joins us as a Clinical Trial Manger and will be supporting the EQUATOR program for acute Graft-Versus-Host Disease.? ? Annie previously worked as a Sr. Project Manager in both Project Management and Clinical Operations at Nitto BioPharma and as a coordinator at UCSD Health. ? In her spare time, Annie enjoys Pilates, cycling and catching the occasional halibut under the Coronado Bridge. ? Welcome Annie!

"At Equillium, our community matters!" Thank you Life Science Cares San Diego and Feeding San Diego for your partnership! #LifeScienceCaresSanDiego #FeedingSanDiego #CommunityDay #SocialResponsibility #FunWellnessDay